-
About
- Health
-
Patient Care
I Want To...
-
Research
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
-
School of Medicine
I Want to...
Research and Clinical Trials
Clinical trials come from the discoveries made in basic science laboratories. By taking these investigations and discoveries, researchers and scientists can create new therapies and treatments. Below are the listings of our current clinical trials.
Localized
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
---|---|---|---|
R1216
| Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck | Ana Kiess
| Amber Michalik |
HPV-Associated
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
---|---|---|---|
J1918 | Adjuvant Therapy for High-Risk HPV16-positive Oropharynx Cancer Patients with Durvalumab (MEDI4736) and MEDI0457 (INO-3112) | Carole Fakhry | Bhavika Patel |
Recurrent or Metastatic Neoadjuvant
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
---|---|---|---|
J1923 | Preoperative Immune Checkpoint Inhibitor for Patients with Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (RM-SCCHN) Undergoing Surgical Resection (CA209-9H7) | Patrick Forde | Michelle Thomas |
Recurrent or Metastatic
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
---|---|---|---|
J15183 | A Phase II Trial of Reirradiation Combined with Open Label MK-3475 (Pembrolizumab) in Patients with Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ana Kiess | Riley McIntryre |
J15117 | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors (CheckMate 358) | William Sharman | Jing Ye |
Phase IIa
Trial # | Name of Clinical Trial | Principal Investigator | Study Coordinator |
---|---|---|---|
J1480 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents (Protocol Number: ML28897/PRO 02) | Adrain Murphy | Kimberly White |
Detailed descriptions of these trials are available at www.clinicaltrials.gov